Takeda Pharmaceutical Co. Ltd (TKPYY.PK) and Millennium said it received conditional marketing authorisation for Adcetris from European Commission. The marketing authorization is based on a positive benefit-risk assessment and a high overall response rate. Takeda plans to launch Adcetris, an antibody-drug conjugate directed to CD30 across Europe, starting from coming weeks.
The authorization is for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
For comments and feedback: editorial@rttnews.com